Top Story Today
The Nobel Laureate's CRISPR Company Is Dead. The Science Wasn't the Problem.
Caribou Biosciences, co-founded by Nobel laureate Jennifer Doudna, is shutting down after failing to raise the cash needed for later-stage cancer trials. The company's stock cratered roughly 46% in a single day, landing around $0.62 per share for a company that raised over $300 million at its 2021 IPO. Caribou's allogeneic CAR-T therapy actually posted strong Phase 1 data (82% response rate in lymphoma patients), but the financing environment for off-the-shelf cell therapies has turned brutal. It joins Spotlight Therapeutics and Prime Medicine in a growing list of CRISPR-era casualties.
Why it matters: Caribou's closure exposes a widening gap across gene editing: the science keeps working, but the business model can't sustain it. When even a Nobel pedigree and credible clinical data can't attract capital, the entire cell and gene therapy sector has a funding problem that no amount of good data can solve.
Read more →Clinical Wins and Regulatory Moves
A Takeda Spinout Just Cracked Parkinson's Most Stubborn Problem
Cerevance's solengepras gave Parkinson's patients back 37 extra minutes of normal movement per day in the Phase 3 ARISE trial, hitting its primary endpoint with statistical significance. Born from a Takeda restructuring with just $36 million, the company now heads to the FDA. In a disease where patients lose hours of their waking day to "off" periods, even half an hour matters.
Read more →Pfizer's $43B Seagen Bet Gets a New Chapter in Breast Cancer
The FDA approved tucatinib as the first oral targeted pill added to maintenance therapy for HER2-positive metastatic breast cancer. Patients gained an extra 8.6 months of disease control in the HER2CLIMB-05 trial. The label expansion moves tucatinib into first-line maintenance, dramatically widening the patient pool and potentially transforming the asset into a billion-dollar franchise.
Read more →Celiac Disease Might Finally Get Its First-Ever Drug
Argenx posted positive Phase 2 data for FB102 in celiac disease, protecting patients' gut lining even during deliberate gluten exposure. The disease affects 1% of the global population, and the only current treatment is a lifelong gluten-free diet. No drug has ever been approved for the condition; argenx is now charging toward a pivotal trial.
Read more →One Shot to Delete High Cholesterol Forever: CRISPR Heads to Humans
Editas Medicine got the green light to test EDIT-401, a single-dose CRISPR therapy that cut LDL cholesterol by 90%+ in primates by boosting the liver's own cholesterol-clearing machinery. The Phase 1/2 trial in Australia targets familial hypercholesterolemia, with early data expected in 2027. This is CRISPR stepping beyond rare diseases into the world's leading killer: cardiovascular disease.
Read more →Deals and M&A
Telix Paid $2.35 Billion for a Factory. That's the Point.
Telix Pharmaceuticals is acquiring ITM Isotope Technologies for up to $2.35 billion, and the real prize isn't the pipeline. ITM is one of the world's largest producers of lutetium-177, the radioactive isotope the entire radiopharmaceutical industry runs on. With manufacturing bottlenecks already disrupting Novartis's Pluvicto supply, Telix is betting that owning the raw materials matters more than owning the drugs.
Read more →Zymeworks Bought an Entire Company Without Issuing a Single Share
Zymeworks closed its $929 million acquisition of Theravance Biopharma using a clever non-recourse financing structure that pledges Theravance's own Yupelri revenue to service the debt. Zero equity dilution. The deal transforms Zymeworks from a clinical-stage antibody shop into a diversified company with a steady quarterly revenue stream from a growing COPD drug.
Read more →Policy and Patent Battles
A Small San Diego Company Just Blocked Keytruda in Eight Countries
A Dutch court ruled that Merck's subcutaneous Keytruda infringes a Halozyme patent, barring sales in eight European countries. That's a direct hit to Merck's lifecycle strategy for its $31.7 billion blockbuster, which needs the subcutaneous version to survive patent cliffs starting around 2028. Halozyme has now won injunctions in both Germany and the Netherlands.
Read more →PhRMA Sues to Block International Drug Price Benchmarking
The pharmaceutical industry's biggest trade group filed a lawsuit challenging the Trump administration's GLOBE rule, which would tie Medicare drug prices to what 19 other countries pay. After losing a string of legal challenges to the Inflation Reduction Act (including six Supreme Court petition denials), PhRMA is trying a new angle: arguing CMS stretched its authority without Congressional approval.
Read more →Science and Discovery
MIT's AI Just Killed the Freezer for mRNA Vaccines
MIT researchers used AI to engineer mRNA vaccine packaging that survives 12 months at room temperature. Mice showed immune responses comparable to fresh, frozen doses. If this holds up in humans, it could slash cold-chain logistics costs by 86% and finally solve the distribution problem that kept mRNA vaccines out of the developing world during COVID.
Read more →